Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All drugs

Vorasidenib

Voranigo

Stage Approved

Sponsor Servier

Route oral

Modality small molecule

Class mutant IDH1/IDH2 inhibitor

Mechanism brain-penetrant dual inhibitor of mutant IDH1 and IDH2

Target IDH1 R132 (mutant)

Target IDH2 R172 (mutant)

Sources

fda, as of 2026-11-07

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31405fee-55b7-4857-987e-2724ee76be84

Voranigo (vorasidenib) USPI, DailyMed setid 31405fee-55b7-4857-987e-2724ee76be84 (version 9, 06.20.2026), label text re-used from the 10.27.2026 pull: sections 1, 2, 5.1, 6.1, 14 (INDIGO NCT04164901)

Brief source I1

publication, as of 2026-11-07

https://pubmed.ncbi.nlm.nih.gov/37272516/

Mellinghoff IK et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma (INDIGO). N Engl J Med 2023;389:589-601. PMID 37272516 (abstract, carried from 10.27.2026 brief source G18)

Brief source I2

company_release, as of 2026-11-07

https://servier.mediaroom.com/

Servier release 05.31.2026, INDIGO extended follow-up at ASCO 2026 (company release; carried from G19)

Brief source I3

company_release, as of 2026-11-07

https://servier.mediaroom.com/2026-11-06-Servier-Highlights-Growing-Neuro-Oncology-Portfolio-with-New-Data-Across-Pediatric-and-Adult-Glioma-at-SNO-2026

Servier release 11.06.2026: nine abstracts, five orals at SNO 2026 (11.12 to 11.15.2026, Philadelphia), incl. INDIGO 41.6-month follow-up, seizure and QoL analysis, real-world TTNI in 499 grade 2 patients and an 80-patient grade 3 cohort (company release)

Brief source I4

publication, as of 2026-11-07

https://aacrjournals.org/clincancerres/article/27/16/4491/671595/

Mellinghoff IK et al. Vorasidenib Phase 1 in recurrent or progressive glioma. Clin Cancer Res 2021;27:4491-4499 (abstract via search record)

Brief source I12

publication, as of 2026-11-07

https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS2103

Alliance A072301 (VORTEX) design, J Clin Oncol 44(16_suppl) TPS2103, ASCO 2026; ClinicalTrials.gov NCT07215910

Brief source I17

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT04164901

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT07215910

Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination With the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT06809322

Vorasidenib as Maintenance Treatment After First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma: a Placebo-controlled, Triple-blind, Randomized Phase III Study (VIGOR)

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT06780930

A Phase 3, Multicenter, Randomized, Double-blind, Placebo- Controlled Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT06478212

A Phase 1b/2, Multicenter Study of Vorasidenib in Combination With Temozolomide (TMZ) in Participants With IDH1- or IDH2-mutant Glioma

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT05484622

A Phase 1, Safety Lead-In and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination With Pembrolizumab in Subjects With Recurrent or Progressive IDH-1 Mutant Glioma

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT05609994

ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT07629089

VALIENT: Phase 1 Clinical Trial of VorAsidenib in Combination With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

INDIGO

Registry NCT04164901

Phase Phase 3

Status Active, not recruiting

Enrollment 331

Start 2020-01-05

Primary completion 2022-09-06

Study completion 2028-05

Catalyst Primary completion. 09.06.2022. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Vorasidenib 40 mg daily

Dose 40 mg

Regimen once daily

Comparator placebo

Population grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery only (n = 168 vs 163)

Estimand ITT

PFS hazard ratio vs placebo (BIRC): 0.39 HR, primary analysis

time to next intervention hazard ratio: 0.26 HR, primary analysis

median time to next intervention, placebo: 17.8 months, primary analysis

median PFS, vorasidenib: 27.7 months, NEJM 2023

median PFS, placebo: 11.1 months, NEJM 2023

median PFS, extended follow-up: 44.1 months, ASCO 2026, preliminary

objective response rate, extended follow-up: 20.8%, ASCO 2026, preliminary

grade 3 or higher adverse events: 22.8%, NEJM 2023 (placebo 13.5%)

grade 3 or 4 ALT increase (pooled): 9%, label

grade 3 or 4 AST increase (pooled): 4.8%, label

permanent discontinuation for ALT elevation: 2.9%, label

Vorasidenib Phase 1

Vorasidenib, non-enhancing glioma

Dose Phase 1 doses

Regimen once daily

Population recurrent non-enhancing IDH-mutant glioma (n = 22)

Estimand Single arm

objective response rate: 18%, Phase 1

median PFS: 36.8 months, Phase 1

VORTEX (Alliance A072301)

Registry NCT07215910

Phase Phase 3

Status Recruiting

Enrollment 408

Start 2026-06-24

Primary completion 2033-05-31

Study completion 2040-01

Catalyst Primary completion. 05.31.2033. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

RT then TMZ + vorasidenib

Dose 40 mg

Regimen once daily

Comparator placebo

Population newly diagnosed grade 3 IDH-mutant astrocytoma

Estimand ITT

VIGOR

Registry NCT06809322

Phase Phase 3

Status Recruiting

Enrollment 468

Start 2026-01-16

Primary completion 2035-04-13

Study completion 2037-05-31

Catalyst Primary completion. 04.13.2035. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

NCT06780930

Registry NCT06780930

Phase Phase 3

Status Active, not recruiting

Enrollment 57

Start 2024-10-18

Primary completion 2026-05-07

Study completion 2030-10-31

Catalyst Primary completion. 05.07.2026. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

NCT06478212

Registry NCT06478212

Phase Phase 1/2

Status Active, not recruiting

Enrollment 51

Start 2025-01-22

Primary completion 2027-11

Study completion 2028-06

Catalyst Primary completion. 11.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

NCT05484622

Registry NCT05484622

Phase Phase 1

Status Active, not recruiting

Enrollment 60

Start 2023-01-20

Primary completion 2026-02-12

Study completion 2027-08-30

Catalyst Primary completion. 02.12.2026. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ViCToRy

Registry NCT05609994

Phase Phase 1

Status Recruiting

Enrollment 48

Start 2025-07-15

Primary completion 2027-08

Study completion 2029-08

Catalyst Primary completion. 08.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

VALIENT

Registry NCT07629089

Phase Phase 1

Status Not yet recruiting

Enrollment 36

Start 2026-11-30

Primary completion 2030-06-30

Study completion 2035-06-30

Catalyst Primary completion. 06.30.2030. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Catalyst SNO 2026: INDIGO 41.6-month, seizure/QoL, real-world grade 2 and 3. 11.12.2026. Servier release 11.06.2026; meeting 11.12 to 11.15.2026.